What might the German election mean for markets?
We believe biotech's long-term historical drivers, demographics and mergers and acquisitions (M&A) activity to secure patent protected drugs, may outlast near-term political headwinds and should lead investors to consider bio-pharma from a longer-term perspective. Biotech valuations also currently appear attractive relative to the broader market and look less crowded than other growth sectors. Over the short term we see potential opportunities in select individual biotech and pharma names.
We see three factors that potentially support Japanese equities going forward: 1. Improving earnings outlook amid a strengthening domestic economy and synchronized global expansion. 2. Currently attractive equity valuations compared to developed market peers. 3. Continued monetary stimulus from the Bank of Japan and a potentially stable yen.